Xtant Medical Holdings, Inc. (XTNT)
NYSE American · Healthcare · Medical Devices
$0.3286−3.66%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $46.1M
- 52-week range
- $0.27 – $0.95
- 52-week change
- −49.25%
- EPS (trailing)
- −$0.08
- Next earnings
- Nov 10, 2026
Fiscal year to Dec 2025
- Revenue
- $134M (+14.21%)
- Net income
- $5K
- Operating margin
- 5.4%
- Diluted EPS
- $0.03
- Free cash flow
- $10.2M
From the company’s annual report on SEC EDGAR.
About Xtant Medical Holdings, Inc.
Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. It offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, a moldable demineralized bone matrix; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor Pro, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, an aseptically processed and viable bone allograft; and nanOss products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.
Headquarters: Belgrade, United States · 151 employees · xtantmedical.com